Global Tourettes Syndrome Drugs Market to grow with a CAGR of 5.80%
Increasing
healthcare infrastructure and initiatives taken by the government are the major
drivers for the Global Tourettes Syndrome Drugs Market
According
to TechSci Research report, “Global Tourettes Syndrome Drugs Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Tourettes Syndrome
Drugs Market has valued at USD 2.40 billion in 2022 and is anticipated to
witness an impressive growth in the forecast period with a CAGR of 5.80%
through 2028. This can be ascribed to collaborations and partnerships among
leading companies with a diverse approach to merge the expertise of individual
companies and to strengthen their position in the market. Emerging therapies
are drivers for the Global Tourette's Syndrome Drugs Market. The development
and introduction of new and innovative treatments play a crucial role in
advancing the field of Tourette's syndrome management. The introduction of new
therapies provides healthcare providers with additional tools for managing
Tourette's syndrome. This allows for a more diverse range of treatment options
to better address the unique needs of individual patients. Emerging therapies
often aim to improve the effectiveness of treatment in reducing tics and
associated symptoms. Enhanced efficacy can lead to better outcomes for
individuals with Tourette's syndrome. New therapies may be designed with a
focus on minimizing side effects. This can lead to improved tolerability and
medication adherence, enhancing the overall treatment experience for patients. Emerging
therapies may target novel mechanisms of action in the brain, offering new
insights into the neurobiology of Tourette's syndrome and potentially leading
to more effective treatments. Some emerging therapies may be used in
combination with existing treatments, allowing for a synergistic approach to
managing tics and associated symptoms.
Browse
over XX market data Figures and spread through 110
Pages and an in-depth TOC on " Global Tourettes Syndrome Drugs Market”
Individuals
with Tourette's syndrome experience repetitive, involuntary movements and
unwanted sounds known as tics. Additionally, Tourette's syndrome often
co-occurs with various other conditions, including attention deficit
hyperactivity disorder, obsessive-compulsive disorder, depression, and sleep
disturbances. These comorbid conditions significantly impact patients' quality
of life and lead to impaired psychosocial functioning. Fortunately, there are
cost-effective non-antipsychotic and atypical antipsychotic drugs such as
quetiapine, olanzapine, risperidone, and aripiprazole that can effectively
suppress tics in individuals with Tourette's syndrome. In March 2023, Emalex Biosciences has reported the
initiation of dosing for the first patient in its Phase 3 clinical trial, which
is focused on assessing ecopipam as a treatment for Tourette Syndrome. During
the open-label phase of the study, trial participants will receive ecopipam for
a duration of 12 weeks. Following this period, individuals who exhibit a
minimum 25% reduction in the Yale Global Tic Severity Scale-Total Tic Score
(YGTSS-TTS) at both week 8 and week 12 will undergo randomization. In the subsequent
double-blind phase, they will either continue receiving ecopipam or switch to a
placebo until a relapse occurs, for a maximum additional 12 weeks. The primary
measure of efficacy will be the difference in time-to-relapse between the two
groups. Ecopipam is a groundbreaking dopamine-1 receptor antagonist. In
contrast, the antipsychotic medications currently sanctioned for treating
Tourette syndrome act on the dopamine-2 receptor and are linked to severe side
effects. Individuals who participated in the Phase 2b D1AMOND study did not
display noticeable signs of adverse movements, excessive weight gain, or the
metabolic complications frequently associated with antipsychotic drugs.
Efficacy and side effects are significant
challenges in the Global Tourette's Syndrome Drugs Market. Developing drugs for
Tourette's syndrome that effectively reduce tics and associated symptoms while
minimizing side effects is a complex task. Striking the right balance between efficacy
and side effects can be challenging, as some medications may suppress tics but
come with a range of adverse effects. Individual responses to medications can vary
widely. What works well for one person with Tourette's syndrome may not be as
effective for another. Tailoring treatment to each patient's unique needs is
essential but can be challenging. Many medications used to treat Tourette's
syndrome, such as antipsychotic drugs, may have side effects that can be
problematic. These side effects can include weight gain, sedation, movement
disorders (such as parkinsonism or tardive dyskinesia), metabolic changes, and
hormonal imbalances. Addressing these adverse effects is a key challenge in
medication management.
Global Tourettes Syndrome Drugs Market segmentation
is based on Product, Distribution Channel, By Company, and Region. Based on Product, Global Tourettes Syndrome
Drugs Market is segmented into Antipsychotics, Non-antipsychotics. Antipsychotics are a class of medications
commonly used in the treatment of Tourette's syndrome (TS) to manage tics and
associated symptoms. While the name antipsychotic may suggest a primary use for
treating psychotic disorders, these drugs have proven effective in addressing
the neurological symptoms of TS. Antipsychotic
medications primarily target neurotransmitter systems in the brain,
particularly the dopamine system. Dopamine is a chemical messenger that plays a
role in controlling motor movements and regulating mood. In Tourette's
syndrome, there is often an imbalance in dopamine signaling, which is believed
to contribute to the development of tics. Antipsychotics work by blocking dopamine receptors in the brain,
reducing the release of dopamine and modulating its effects. This can help
decrease the frequency and severity of tics in individuals with TS.
Based on Region, the North America segment is the dominating
segment of Global Tourettes Syndrome Drugs Market. The
regulatory environment in North America is conducive to drug development.
Regulatory agencies prioritize patient safety while also facilitating the
approval process for promising treatments. Due to the higher prevalence of
Tourette's syndrome and related neurological disorders in North America, there
is a substantial market demand for effective treatments. This demand drives
investment and competition in the pharmaceutical industry. Many international
pharmaceutical companies collaborate with North American counterparts to
conduct research and clinical trials. This fosters innovation and enhances the
region's leadership in drug development. North America has made significant
strides in raising awareness about Tourette's syndrome among healthcare
professionals, educators, and the public. This contributes to early diagnosis
and better management of the condition. Government funding and support for
Tourette's syndrome research, both at the federal and state/provincial levels,
have been instrumental in advancing treatments and therapies. The North
American market is often seen as a gateway to global markets. Companies that
successfully launch Tourette's syndrome drugs in North America can leverage
their success to expand into other regions.
Asia
Pacific is the fastest-growing region in the Global Tourettes Syndrome Drugs Market.
As awareness of Tourette's syndrome grows in the Asia Pacific region, there is
an increase in the number of individuals being accurately diagnosed with the
condition. This could lead to greater demand for drugs and treatments. The
rising prevalence of Tourette's syndrome in the Asia Pacific region, it would
naturally drive the demand for drugs and treatments to manage the condition. Improvements
in healthcare infrastructure and access to specialized care in the Asia Pacific
region can facilitate better diagnosis and treatment of Tourette's syndrome,
potentially boosting the market for related drugs.
Some of the major companies
operating in the Global Tourettes
Syndrome Drugs Market include:
- AstraZeneca
Plc
- Boehringer
Ingelheim International GmbH
- Eli
Lilly and Co.
- H.
Lundbeck AS
- Johnson
& Johnson Services Inc.
- Mylan
NV
- Otsuka
Holdings Co. Ltd.
- Pfizer
Inc.
- Sun
Pharmaceutical Industries Ltd.
- Teva
Pharmaceutical Industries Ltd.
Download Free Sample Report
Customers can also request
for 10% free customization on this report
“Certain areas, particularly in North
America, are projected to exert significant demand of Tourettes Syndrome Drugs.
The growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global Tourettes
Syndrome Drugs Market in the forecast period," said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based Global management
consulting firm.
Tourettes Syndrome Drugs Market -
Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Target Disease Indication
(Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung
Cancer, Renal Cell Carcinoma), By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized
Neoantigens), By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based
Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies), By Route of
Administration (Intradermal, Intravenous, Subcutaneous), By Region, and
Competition has
evaluated the future growth potential of Global Tourettes Syndrome Drugs Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Tourettes Syndrome Drugs Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com